メタ情報
| meta description平均長 | 150.08 |
|---|
| OGPありページ数 | 37 |
|---|
| Twitterカードありページ数 | 37 |
|---|
内部リンク分析（Internal）
| ユニーク内部リンク数 | 40 |
|---|
| ページあたり内部リンク平均 | 31.92 |
|---|
連絡先候補（Contacts）
このデータの閲覧には会員登録が必要になります。会員登録
キーワード分析（KeywordMap）
ワードクラウド上位
| 語 | 重み |
|---|
| leadership | 1 |
| Chief | 0.888431 |
| Officer | 0.888431 |
| University | 0.834134 |
| career | 0.833309 |
| business | 0.760807 |
| testing | 0.69536 |
| bringing | 0.688386 |
| viral | 0.644715 |
| his | 0.615924 |
| serves | 0.606145 |
| site | 0.603774 |
| roles | 0.579693 |
| strategy | 0.57628 |
| assays | 0.55979 |
| experience | 0.557468 |
| strategic | 0.552268 |
| has | 0.549562 |
| She | 0.548417 |
| regulatory | 0.547269 |
| compliance | 0.54717 |
| senior | 0.543463 |
| where | 0.543463 |
| Healios | 0.520743 |
| held | 0.513313 |
| operations | 0.507309 |
| Earlier | 0.504938 |
| methods | 0.503397 |
| process | 0.494782 |
| Cell | 0.489297 |
| patients | 0.487158 |
| vector | 0.485891 |
| management | 0.485891 |
| therapies | 0.480671 |
| Our | 0.480671 |
| CDMO | 0.476528 |
| growth | 0.472225 |
| leads | 0.471001 |
| holds | 0.461825 |
| services | 0.461353 |
| transfer | 0.45572 |
| Testing | 0.45572 |
| technology | 0.454829 |
| you | 0.44925 |
| her | 0.449149 |
| positions | 0.449149 |
| your | 0.448622 |
| studies | 0.44599 |
| life | 0.438442 |
| GMP | 0.438117 |
共起語上位
| 語1 | 語2 | スコア | 共起ページ数 |
|---|
| Advanced | Therapies | 5.060806 | 540 |
| Advanced | Minaris | 4.646195 | 641 |
| Follow | LinkedIn | 4.509422 | 148 |
| LinkedIn | stay | 4.503342 | 148 |
| stay | updated | 4.503342 | 148 |
| innovations | insights | 4.473428 | 148 |
| intro | section | 4.252979 | 108 |
| does | section | 4.252979 | 108 |
| company | news | 4.230233 | 148 |
| Whether | you | 4.131226 | 172 |
| does | not | 4.086094 | 108 |
| exist | not | 4.050372 | 108 |
| cell | gene | 4.03813 | 380 |
| ideal | make | 3.985263 | 104 |
| company | innovations | 3.979931 | 148 |
| industry | updated | 3.942537 | 148 |
| innovations | news | 3.925067 | 111 |
| industry | insights | 3.912623 | 148 |
| commitment | reach | 3.851701 | 104 |
| early | stage | 3.792505 | 148 |
| Asia | Europe | 3.721102 | 71 |
| Follow | stay | 3.708728 | 111 |
| LinkedIn | updated | 3.703342 | 111 |
| EMA | FDA | 3.687468 | 64 |
| insights | updated | 3.676843 | 111 |
| helping | innovators | 3.676748 | 100 |
| Chief | Officer | 3.657199 | 109 |
| dedicated | helping | 3.651387 | 100 |
| gene | therapy | 3.648401 | 296 |
| Whether | succeed | 3.553092 | 100 |
| does | intro | 3.517632 | 81 |
| ideal | partner | 3.515879 | 104 |
| does | exist | 3.485983 | 81 |
| States | United | 3.426309 | 40 |
| allogeneic | autologous | 3.423561 | 47 |
| EMA | PMDA | 3.38055 | 48 |
| not | section | 3.369778 | 81 |
| launch | preparing | 3.341545 | 75 |
| more | than | 3.339537 | 76 |
| Minaris | Therapies | 3.314762 | 405 |
| long | term | 3.271844 | 36 |
| Clarke | Collins | 3.271844 | 36 |
| President | Vice | 3.236107 | 32 |
| cell | therapy | 3.229861 | 310 |
| Follow | biologics | 3.222722 | 100 |
| company | insights | 3.21319 | 111 |
| industry | stay | 3.206564 | 111 |
| industry | innovations | 3.206564 | 111 |
| analytical | biosafety | 3.198558 | 126 |
| commitment | make | 3.166601 | 79 |